

HYALURONIC ACID DERIVATIVES

Federal Employee Program. PRIOR APPROVAL REQUEST

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services

physician portion and submit this completed form Fax: 1-877-378-4727 **Provider Information** (required) Patient Information (required) Date: Provider Name: NPI: Patient Name: Specialty: Date of Birth: □Male ☐Female Office Phone: Office Fax: Sex: Street Address: Office Street Address: City: State: Zip: City: State: Zip: Patient ID: Physician Signature: PHYSICIAN COMPLETES FOR CLAIMS ADJUDICATED THROUGH THE PHARMACY BENEFIT: For Standard and Basic Option patients Gel-ONE, GelSyn-3, Hyalgan, and Supartz are preferred products. Please consider prescribing a preferred product. Patients who switch to a preferred product will be eligible for 2 copays at no cost in the benefit year. **NOTE**: Form must be completed in its **entirety** for processing Please select medication: **□**Durolane □GenVisc 850 **□**Orthovisc **□**Synvisc-One □Visco-3 □**Euflexxa** □Hyalgan **□Sodium Hyaluronate □Supartz □Gel-ONE □**Hymovis **□**Triluron **□**Synojoynt □GelSyn-3 **□**Monovisc □TriVisc **□**Synvisc **Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit Is this request for brand or generic? □Brand 1. Non-Preferred Product Request (Standard/Basic Option), for claims adjudicated through the pharmacy benefit: Would you like to participate in this program and switch the patient to GelSyn-3, Hyalgan, Supartz, or Gel-ONE? Please select the answer below: ☐Yes (please select the preferred product): ☐Gel-ONE ☐GelSyn-3 □Hyalgan □ Supartz □No: Does the patient have an intolerance or contraindication or have they had an inadequate treatment response to TWO preferred products? □Yes □No*

■Synvisc-One

□TriVisc

□Triluron

□Visco-3

*If NO, is there a clinical reason for not trying TWO of the preferred medications? \Box Yes \Box No

□Synvisc

3. Will the injections be used to treat osteoarthritis of the knee? □Yes □No

□Synojoynt

□Sodium Hyaluronate

4. Please specify the knee(s) being treated: \(\subseteq \text{Left knee only}\) \(\subseteq \text{Right knee only}\)

PLEASE PROCEED TO PAGE 2 FOR ADDITIONAL QUESTIONS

PAGE 1 of 2



HYALURONIC ACID DERIVATIVES

Federal Employee Program. PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs.	Please complete the patient portion.	, and have the prescribing physician complete th
hysician portion and submit this completed form.		

PAGE 2 - PHYSICIAN COMPLETES		
Patient Name:	DOB:	Patient ID: R
		duronic acid agent? Please select answer below: her knee, please complete both Initiation and Continuation.
□ INITIATION of therapy, plea	ase answer the following question	is:
reduction (for persons wh patellar taping, wearing of cardiovascular (aerobic) a	o are overweight), participation in f wedged insoles, thermal agents, activity, such as walking, biking, s	WO or more of the following: resistance exercise, weight in self-management programs, wearing of medially directed walking aids, physical therapy, occupational therapy, or stationary bike, or aquatic exercise? □Yes □No
	intolerance or contraindication or h efficacy lasted less than 8 weeks	have they had an inadequate treatment response to intra-articular s? □Yes □No
c. Does the patient have radi	iologic confirmation of a Kellgrei	n-Lawrence Scale score of grade 2 or greater? □Yes □No
the following: Acetamino	phen (Tylenol), oral NSAIDs, or	have they had inadequate treatment response to TWO or more of topical NSAIDs? □Yes □No
☐ CONTINUATION (PA rene	wal) of therapy, please answer th	e following questions:
		e previous course of treatment? □Yes □No
	nted reduction of dosing NSAIDs ment cycle? □Yes □No	or other analgesic during the 12-month period following the last
c. Have at least 12 months e	lapsed since the last injection of t	he prior treatment cycle? □Yes □No

PAGE 2 of 2